KRAS and neoplasm: In the Cancer Genome Atlas, survival and recurrence rates were found to be significantly different in pancreatic adenocarcinoma patients with mutations in the DKN2A, TP53, TTN, KCNJ18, and KRAS genes, which are mutated in the early stages of tumor formation and have a high cellular prevalence, compared to patients without mutations in those candidate genes.